Ponatinib D8

• CAT Number: I017425
• CAS Number: 1562993-37-6
• Molecular Formula: C₂₉H₁₉D₈F₃N₆O
• Molecular Weight: 540.61
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
• InChI: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)/i12D2,13D2,14D2,15D2
• InChIKey: PHXJVRSECIGDHY-DHNBGMNGSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

Ponatinib D8 (Cat No.:I017425) is a deuterium-labeled version of Ponatinib, an orally active kinase inhibitor. Ponatinib demonstrates potent inhibitory activity against multiple kinases, with IC50 values of 0.37 nM for Abl, 1.1 nM for PDGFRα, 1.5 nM for VEGFR2, 2.2 nM for FGFR1, and 5.4 nM for Src, respectively. By targeting these kinases, Ponatinib exhibits potential therapeutic effects in various diseases, particularly those driven by dysregulated kinase signaling pathways.

Reference

[1]. O’Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412.